Paper21079145
The evolving role of histology in the management of advanced non-small-cell lung cancer.
Langer CJ and 4 others. J Clin Oncol, 2010. Cited by 240 papers, by iCite.
Cite this record
ConductScience Library. The evolving role of histology in the management of advanced non-small-cell lung cancer. Papers, record 21079145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21079145
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Humans |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02716038 | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | Background | ClinicalTrials.gov | |
| NCT05965102 | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 21768461 | Role of cytology in the management of non-small-cell lung cancer. | https://conductscience.org/library/papers/21768461 |
Source PubMed
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 240 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42530663 | Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP). | Clin Exp Metastasis | 2026 | https://conductscience.org/library/papers/42530663 | PubMed |
| 41599703 | Tumor Characterization Using [18F]FDG PET Radiomics in a PD-L1-Positive NSCLC Cohort. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41599703 | PubMed |
| 41465456 | Overexpression of GM3 and Ganglioside Pattern Remodeling in Lung Adenocarcinoma Brain Metastases Identified by Ion Mobility Mass Spectrometry. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465456 | PubMed |
| 41378286 | Long-term outcomes and patterns of failure after empiric SBRT for presumed early-stage lung tumors. | Front Oncol | 2025 | https://conductscience.org/library/papers/41378286 | PubMed |
| 41353554 | Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy. | J Pharm Health Care Sci | 2025 | https://conductscience.org/library/papers/41353554 | PubMed |
| 41210989 | Down-regulation of MFNG promotes the metastatic potential of lung adenocarcinoma by regulating TGF-β/Smad signaling. | iScience | 2025 | https://conductscience.org/library/papers/41210989 | PubMed |
| 41023740 | Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/41023740 | PubMed |
| 40938464 | The functions and regulation of transcription factor YBX1 in cancers. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40938464 | PubMed |
| 40852643 | Sonodynamic Therapy-Based DNA Nanocarriers with Hypoxia-Inducible Factor-1α Silencing Activation for Precision Lung Cancer Therapy. | Biomater Res | 2025 | https://conductscience.org/library/papers/40852643 | PubMed |
| 40759444 | Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40759444 | PubMed |
| 40047406 | Regulation of lung cancer initiation and progression by the stem cell determinant Musashi. | Elife | 2025 | https://conductscience.org/library/papers/40047406 | PubMed |
| 40028322 | Exosome tropism and various pathways in lung cancer metastasis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40028322 | PubMed |
| 39952933 | One-carbon metabolism is distinct metabolic signature for proliferative intermediate exhausted T cells of ICB-resistant cancer patients. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/39952933 | PubMed |
| 39633593 | TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China. | Biomark Med | 2024 | https://conductscience.org/library/papers/39633593 | PubMed |
| 39385301 | CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma. | Cell Biosci | 2024 | https://conductscience.org/library/papers/39385301 | PubMed |
| 38862862 | Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry. | Clin Transl Oncol | 2024 | https://conductscience.org/library/papers/38862862 | PubMed |
| 38827178 | First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis. | Ther Adv Med Oncol | 2024 | https://conductscience.org/library/papers/38827178 | PubMed |
| 38679648 | miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review. | J Egypt Natl Canc Inst | 2024 | https://conductscience.org/library/papers/38679648 | PubMed |
| 37859595 | MicroRNA‑mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications (Review). | Oncol Rep | 2023 | https://conductscience.org/library/papers/37859595 | PubMed |
| 37612622 | Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37612622 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21079145
GET https://conductscience.org/api/papers/v1/21079145/cited_by?page=2